Literature DB >> 1998973

Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guérin therapy for locally metastatic melanoma.

M H Cohen1, R J Elin, B J Cohen.   

Abstract

Four patients developed serious hypotension and signs of disseminated intravascular coagulation shortly after a second round of Tice bacillus Calmette-Guérin (BCG) injections into locally recurrent cutaneous melanoma satellite nodules. Each of these patients survived following intensive therapy with isoniazid, pyridoxine, steroids, pressors, antibiotics, and cardio-renal support including, in one case, three acute hemodialyses. Plasma specimens from two of the four patients caused gelation of lysate from the amebocytes of Limulus polyphemus, indicating the presence of endotoxin or an endotoxin-like substance. In vitro studies on the BCG preparations led us to conclude that this endotoxin activity in the plasma is not the result of direct injection of endotoxin with the BCG preparation, but rather from release of endotoxin from endogenous sources, such as the intestinal tract during a period of relative hypotension following an allergic reaction. Prior immunity appeared to be the consistent factor in the toxic reactions reported herein. Finally, we present recommendations for serial monitoring of these patients and discuss the use of an alternative agent for intralesional therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1998973     DOI: 10.1007/bf01789050

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

1.  Acquired storage pool disease in platelets during disseminated intravascular coagulation.

Authors:  F I Pareti; A Capitanio; P M Mannucci
Journal:  Blood       Date:  1976-10       Impact factor: 22.113

2.  Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG.

Authors:  L Nathanson
Journal:  Cancer Chemother Rep       Date:  1972-10

3.  Are enteric endotoxins able to escape from the intestine?

Authors:  H Gans; K Matsumoto
Journal:  Proc Soc Exp Biol Med       Date:  1974-12

4.  Demonstration of a lethal endotoxemia in experimental occlusion of the superior mesenteric artery.

Authors:  P Cuevas; J Fine
Journal:  Surg Gynecol Obstet       Date:  1971-07

5.  Effect of anticoagulants on delayed hypersensitivity reactions.

Authors:  S Cohen; B Benacerraf; R T McCluskey; Z Ovary
Journal:  J Immunol       Date:  1967-02       Impact factor: 5.422

Review 6.  Immunological factors which influence response to immunotherapy in malignant melanoma.

Authors:  D Morton; F R Eilber; R A Malmgren; W C Wood
Journal:  Surgery       Date:  1970-07       Impact factor: 3.982

7.  Axillary lymphadenopathy: a complication of BCG immunotherapy for melanoma.

Authors:  P C Briggs; F R Heckler
Journal:  Plast Reconstr Surg       Date:  1988-06       Impact factor: 4.730

8.  Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.

Authors:  M H Cohen; J M Jessup; E L Felix; J L Weese; R B Herberman
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

9.  Mycotic abdominal aortic aneurysm induced by immunotherapy with bacille Calmette-Guérin vaccine for malignancy.

Authors:  J M Woods; J Schellack; M T Stewart; D R Murray; S W Schwartzman
Journal:  J Vasc Surg       Date:  1988-06       Impact factor: 4.268

10.  Granulomatous hepatitis as a late complication of BCG immunotherapy.

Authors:  T Flippin; B Mukherji; Y Dayal
Journal:  Cancer       Date:  1980-10-15       Impact factor: 6.860

View more
  7 in total

Review 1.  Intralesional Immunotherapy for Metastatic Melanoma: The Oldest and Newest Treatment in Oncology.

Authors:  Mark B Faries
Journal:  Crit Rev Oncog       Date:  2016

2.  Keyhole limpet hemocyanin immunotherapy of murine bladder cancer.

Authors:  D L Lamm; J I DeHaven; D R Riggs; C Delgra; R Burrell
Journal:  Urol Res       Date:  1993-01

Review 3.  Developments in Intralesional Therapy for Metastatic Melanoma.

Authors:  Sarah Sloot; Omar M Rashid; Arnod A Sarnaik; Jonathan S Zager
Journal:  Cancer Control       Date:  2016-01       Impact factor: 3.302

Review 4.  In-transit metastatic cutaneous melanoma: current management and future directions.

Authors:  Ayushi Patel; Michael J Carr; James Sun; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2021-05-17       Impact factor: 5.150

Review 5.  Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma.

Authors:  Dejan Vidovic; Carman Giacomantonio
Journal:  Cancers (Basel)       Date:  2020-05-22       Impact factor: 6.639

Review 6.  Topical and intralesional therapies for in-transitmelanoma.

Authors:  Michael A Henderson
Journal:  Melanoma Manag       Date:  2019-09-02

7.  Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.

Authors:  Paul Toomey; Krithika Kodumudi; Amy Weber; Lisa Kuhn; Ellen Moore; Amod A Sarnaik; Shari Pilon-Thomas
Journal:  PLoS One       Date:  2013-07-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.